Spero Therapeutics, Inc.
(NASDAQ : SPRO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.49%34.650.9%$1168.91m
JNJJohnson & Johnson
0.62%131.350.7%$908.58m
MRKMerck & Co., Inc.
1.92%85.060.6%$797.24m
BMYBristol-Myers Squibb Company
2.67%46.971.4%$680.66m
ABBVAbbVie, Inc.
2.30%64.432.3%$610.53m
LLYEli Lilly and Company
0.24%110.491.0%$456.04m
NVSNovartis AG Sponsored ADR
0.99%89.460.2%$209.31m
AZNAstraZeneca PLC Sponsored ADR
0.39%44.351.2%$166.53m
GSKGlaxoSmithKline plc Sponsored ADR
0.60%40.200.3%$95.35m
NVONovo Nordisk A/S Sponsored ADR Class B
2.70%51.650.1%$81.50m
SNYSanofi Sponsored ADR
0.89%42.020.2%$56.34m
LCILannett Company, Inc.
4.31%6.7736.6%$10.92m
AKTXAkari Therapeutics Plc Sponsored ADR
-5.37%1.941.6%$3.62m
EPIXESSA Pharma Inc
3.28%1.510.1%$0.03m

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.